101 related articles for article (PubMed ID: 10966074)
21. Endothelial monocyte activating polypeptide II induces endothelial cell apoptosis and may inhibit tumor angiogenesis.
Berger AC; Alexander HR; Tang G; Wu PS; Hewitt SM; Turner E; Kruger E; Figg WD; Grove A; Kohn E; Stern D; Libutti SK
Microvasc Res; 2000 Jul; 60(1):70-80. PubMed ID: 10873516
[TBL] [Abstract][Full Text] [Related]
22. A re-evaluation of fumagillin selectivity towards endothelial cells.
Rodriguez-Nieto S; Medina MA; Quesada AR
Anticancer Res; 2001; 21(5):3457-60. PubMed ID: 11848509
[TBL] [Abstract][Full Text] [Related]
23. Antiangiogenic potential of camptothecin and topotecan.
Clements MK; Jones CB; Cumming M; Daoud SS
Cancer Chemother Pharmacol; 1999; 44(5):411-6. PubMed ID: 10501915
[TBL] [Abstract][Full Text] [Related]
24. Antiangiogenic activity of nasunin, an antioxidant anthocyanin, in eggplant peels.
Matsubara K; Kaneyuki T; Miyake T; Mori M
J Agric Food Chem; 2005 Aug; 53(16):6272-5. PubMed ID: 16076105
[TBL] [Abstract][Full Text] [Related]
25. A novel non-containing-nitrogen bisphosphonate inhibits both in vitro and in vivo angiogenesis.
Hamma-Kourbali Y; Di Benedetto M; Ledoux D; Oudar O; Leroux Y; Lecouvey M; Kraemer M
Biochem Biophys Res Commun; 2003 Oct; 310(3):816-23. PubMed ID: 14550277
[TBL] [Abstract][Full Text] [Related]
26. VE-Cadherin mediates endothelial cell capillary tube formation in fibrin and collagen gels.
Bach TL; Barsigian C; Chalupowicz DG; Busler D; Yaen CH; Grant DS; Martinez J
Exp Cell Res; 1998 Feb; 238(2):324-34. PubMed ID: 9473340
[TBL] [Abstract][Full Text] [Related]
27. Alkylphospholipids inhibit capillary-like endothelial tube formation in vitro: antiangiogenic properties of a new class of antitumor agents.
Zerp SF; Vink SR; Ruiter GA; Koolwijk P; Peters E; van der Luit AH; de Jong D; Budde M; Bartelink H; van Blitterswijk WJ; Verheij M
Anticancer Drugs; 2008 Jan; 19(1):65-75. PubMed ID: 18043131
[TBL] [Abstract][Full Text] [Related]
28. 2-Hydroxy-4,6-diamino-[1,3,5]triazines: a novel class of VEGF-R2 (KDR) tyrosine kinase inhibitors.
Baindur N; Chadha N; Brandt BM; Asgari D; Patch RJ; Schalk-Hihi C; Carver TE; Petrounia IP; Baumann CA; Ott H; Manthey C; Springer BA; Player MR
J Med Chem; 2005 Mar; 48(6):1717-20. PubMed ID: 15771417
[TBL] [Abstract][Full Text] [Related]
29. In vitro and ex vivo antiangiogenic activity of Salvia officinalis.
Keshavarz M; Mostafaie A; Mansouri K; Bidmeshkipour A; Motlagh HR; Parvaneh S
Phytother Res; 2010 Oct; 24(10):1526-31. PubMed ID: 20878705
[TBL] [Abstract][Full Text] [Related]
30. Nitric oxide synthase inhibitors attenuate transforming-growth-factor-beta 1-stimulated capillary organization in vitro.
Papapetropoulos A; Desai KM; Rudic RD; Mayer B; Zhang R; Ruiz-Torres MP; García-Cardeña G; Madri JA; Sessa WC
Am J Pathol; 1997 May; 150(5):1835-44. PubMed ID: 9137106
[TBL] [Abstract][Full Text] [Related]
31. Resveratrol and quercetin inhibit angiogenesis in vitro.
Igura K; Ohta T; Kuroda Y; Kaji K
Cancer Lett; 2001 Sep; 171(1):11-6. PubMed ID: 11485823
[TBL] [Abstract][Full Text] [Related]
32. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
33. Anti-angiogenic activity and mechanism of kaurane diterpenoids from Wedelia chinensis.
Huang W; Liang Y; Wang J; Li G; Wang G; Li Y; Chung HY
Phytomedicine; 2016 Mar; 23(3):283-92. PubMed ID: 26969382
[TBL] [Abstract][Full Text] [Related]
34. Anti-angiogenic actions of pyrrolidine dithiocarbamate, a nuclear factor kappa B inhibitor.
Morais C; Gobe G; Johnson DW; Healy H
Angiogenesis; 2009; 12(4):365-79. PubMed ID: 19882112
[TBL] [Abstract][Full Text] [Related]
35. [Construction of a three-dimensional human angiogenesis model in vitro for antiangiogenic drug selection].
Li B
Di Yi Jun Yi Da Xue Xue Bao; 2004 Oct; 24(10):1167-70. PubMed ID: 15485791
[TBL] [Abstract][Full Text] [Related]
36. A new in vitro model to study endothelial injury.
Wilasrusmee C; Da Silva M; Singh B; Kittur S; Siddiqui J; Bruch D; Wilasrusmee S; Kittur DS
J Surg Res; 2002 May; 104(2):131-6. PubMed ID: 12020132
[TBL] [Abstract][Full Text] [Related]
37. The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis.
Clapp C; Martial JA; Guzman RC; Rentier-Delure F; Weiner RI
Endocrinology; 1993 Sep; 133(3):1292-9. PubMed ID: 7689950
[TBL] [Abstract][Full Text] [Related]
38. Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1.
Chen HH; Zhou HJ; Wu GD; Lou XE
Pharmacology; 2004 May; 71(1):1-9. PubMed ID: 15051917
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and structure-activity relationship of diarylamide derivatives as selective inhibitors of the proliferation of human endothelial cells.
Ogita H; Isobe Y; Takaku H; Sekine R; Goto Y; Misawa S; Hayashi H
Bioorg Med Chem; 2002 Nov; 10(11):3473-80. PubMed ID: 12213461
[TBL] [Abstract][Full Text] [Related]
40. BRN-103, a novel nicotinamide derivative, inhibits VEGF-induced angiogenesis and proliferation in human umbilical vein endothelial cells.
Choi HE; Yoo MS; Choi JH; Lee JY; Kim JH; Kim JH; Lee JK; Kim GI; Park Y; Chi YH; Paik SH; Lee JH; Lee KT
Bioorg Med Chem Lett; 2011 Nov; 21(21):6236-41. PubMed ID: 21963305
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
